ACADIA Pharmaceuticals Inc.
ACAD
주식 순위
#4483
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
주가
$20.20
시가총액
$3.48B
변동 (1일)
2.02%
변동 (1년)
-3.53%
국가
US
거래 ACADIA Pharmaceuticals Inc. (ACAD)
카테고리
Healthcare
ACADIA Pharmaceuticals Inc. (ACAD)의 발행 주식 수
June 2026 기준 발행 주식 수: 171.60M
ACADIA Pharmaceuticals Inc.의 최신 재무 보고서와 주가에 따르면 현재 발행 주식 수는 171.60M입니다. December 2023 말 기준 회사는 163.82M주를 발행했습니다. 발행 주식 수는 일반적으로 주식 분할이나 자사주 매입에 의해 영향을 받습니다.
ACADIA Pharmaceuticals Inc. (ACAD)의 발행 주식 수 기록 (2000 ~ 2026)
매년 말 기준 발행 주식 수
| 연도 | 발행 주식 수 | 변화 |
|---|---|---|
| 2026 (TTM) | 171.60M | 3.55% |
| 2024 | 165.72M | 1.16% |
| 2023 | 163.82M | 1.32% |
| 2022 | 161.68M | 0.74% |
| 2021 | 160.49M | 2.01% |
| 2020 | 157.33M | 6.88% |
| 2019 | 147.20M | 16.29% |
| 2018 | 126.58M | 3.25% |
| 2017 | 122.60M | 5.82% |
| 2016 | 115.86M | 15.13% |
| 2015 | 100.63M | 3.48% |
| 2014 | 97.25M | 13.46% |
| 2013 | 85.72M | 56.23% |
| 2012 | 54.87M | 5.14% |
| 2011 | 52.18M | 35.21% |
| 2010 | 38.59M | 2.98% |
| 2009 | 37.48M | 0.98% |
| 2008 | 37.11M | 5.40% |
| 2007 | 35.21M | 26.10% |
| 2006 | 27.92M | 26.84% |
| 2005 | 22.01M | 112.63% |
| 2004 | 10.35M | 609.62% |
| 2003 | 1.46M | 0.48% |
| 2002 | 1.45M | 20.20% |
| 2001 | 1.21M | 12.90% |
| 2000 | 1.07M | 0.00% |
유사 기업 또는 경쟁사의 발행 주식 수
| 회사 | 발행 주식 수 | 차이 | 국가 |
|---|---|---|---|
| 253.90M | 47.96% |
US
|
|
| 396.00M | 130.77% |
US
|
|
| 478.91M | 179.08% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -63.76% |
NL
|
